Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.
Michael E. Hurwitz(Yale University), Adi Diab(Cleveland Clinic), Jonathan Zalevsky(Nektar Therapeutics (United States)), Brendan D. Curti(Providence Portland Medical Center), Ute Hoch(University of Arizona), Willem W. Overwijk(Weatherford College), Chantale Bernatchez(BMC Software (United States)), Ernesto Iacucci(Nektar Therapeutics (United States)), Arlene O. Siefker‐Radtke(The University of Texas MD Anderson Cancer Center), Mary Tagliaferri(Nektar Therapeutics (United States)), Arjun Vasant Balar(NYU Langone Health), Daniel C. Cho(NYU Langone Health), Christie Fanton(Nektar Therapeutics (United States)), Yi Liu(Boston Children's Hospital), Harriet M. Kluger(Yale Cancer Center), Tuan Nguyen(Nektar Therapeutics (United States)), Mario Sznol(Yale University)
Cited by 22
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k